By analyzing ERBB2 mRNA expression data, researchers identified a group of HER2-negative patients with poor outcomes and potential markers of treatment resistance.
From preclinical research to regulatory approval and clinical adoption, diagnostic testing underpins every stage of ADC ...
The PATHWAY HER2 (4B5) test is now FDA-approved to assess HER2-ultralow status in metastatic breast cancer, expanding its ...
The FDA has approved a companion diagnostic to determine if patients with HR-positive, HER2-ultralow metastatic breast cancer ...
Roche has announced that the FDA has expanded the approval of its PATHWAY® HER2/neu (4B5) Rabbit Monoclonal Primary Antibody test to identify HE ...
In an unusual development, five judges of the Islamabad High Court (IHC) have approached the chief justice of Pakistan and three high court chief justices, requesting them not to advise the ...
As seen in the DESTINY-Breast06 trial, a pproximately 20-25 percent of hormone receptor (HR)-positive, HER2-negative breast cancer patients may be considered HER2-ultralow.1 These patients may now be ...
A larger bench of the Islamabad High Court (IHC) on Thursday summoned the attorney general for Pakistan (AGP) on March 6 in a case relating to the missing persons, saying that there was no ...
One of the ways in which security professionals can assess the security posture of an entire digital ecosystem is by carrying out penetration testing, or pen testing for short. Penetration testing ...
The IHC validation on human knee joint specimens confirmed the ... The P-value represents the probability of obtaining a test statistic as extreme as, or more extreme than, the observed result under ...
(RTTNews) - The U.S. Food and Drug Administration has approved AstraZeneca Plc. (AZN.L, AZN) and Daiichi Sankyo's (DSKYF.PK) ENHERTU (fam-trastuzumab deruxtecan-nxki) for the treatment of adult ...
The approval also highlights the importance of testing metastatic breast cancer tumours for detectable staining with a standard IHC test to identify those who may be eligible for treatment with ...